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Abstract 
Aims 
Luma is a recently discovered, evolutionarily conserved protein expressed in mammalian heart 
that is associated with the LInker of Nucleoskeleton and Cytoskeleton (LINC) complex.  The 
LINC complex structurally integrates the nucleus and the cytoplasm, and plays a critical role in 
mechanotransduction across the nuclear envelope. Mutations in several LINC components in 
both humans and mice result in various cardiomyopathies, implying they play essential, non-
redundant roles. A single amino acid substitution of serine 358 to leucine (S358L) in LUMA is 
the unequivocal cause of a distinct form of arrhythmogenic cardiomyopathy. However, the role 
of Luma in heart has remained obscure. In addition, it also remains to be determined how the 
S358L mutation in Luma leads to cardiomyopathy. 
 
Methods and Results 
To determine the role of Luma in the heart, we first determined the expression pattern of Luma 
in mouse heart. Luma was sporadically expressed in cardiomyocytes throughout the heart, but 
was highly and uniformly expressed in cardiac fibroblasts, and vascular smooth muscle cells. 
We also generated germline null Luma mice and discovered that germline null mutants were 
viable and exhibited normal cardiac function. Luma null mice also responded normally to 
pressure overload induced by transverse aortic constriction. In addition, localization and 
expression of other LINC complex components in both cardiac myocytes and fibroblasts was 
unaffected by global loss of Luma. Furthermore, we also generated and characterized Luma 
S358L knock-in (KI) mice, which displayed normal cardiac function and morphology.  
 
Conclusions 
Our data suggest that Luma is dispensable for murine cardiac development and function and 
that the Luma S358L mutation alone may not cause cardiomyopathy in mice.  
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Introduction 
LUMA (also known as TMEM43 or transmembrane protein 43), is highly evolutionarily 
conserved and is expressed in mammalian heart 1, 2. LUMA was first identified in a proteomics 
screen for nuclear envelope proteins in neuroblastoma cells3  and was subsequently shown to 
localize to the INM where it interacts with the LInker of Nuclear and Cytoskeleton (LINC) 
complex, including LINC complex proteins SUN2, Emerin, Lamins A/C and B1 1, 3-6.  Localization 
of LUMA in mouse embryonic fibroblasts (MEFs) is dependent on A-type Lamins, as Luma is 
mislocalized to the endoplasmic reticulum in MEFs derived from Lamin A/C-deficient mice 1. 
Furthermore, depletion of LUMA in HeLa cells results in mislocalization of Emerin 1, suggesting 
a potential role for LUMA in LINC complex function.  
 
The LINC complex connects the nuclear lamina to the cytoskeleton, 7, 8 provides structural 
support to the nucleus, 7, 9-12 and plays an essential role in regulating gene expression 13-17 and 
mechanotransduction 5, 13-15, 18-21. Many mutations in genes that encode either core components 
or regulators/ effectors of the LINC complex, including Emerin, Lamins A/C, B1, and B2, 
Nesprins, and SUN-domain proteins, have been identified as causing skeletal or cardiac 
myopathy 2, 18, 22-32. Human genetic linkage studies have revealed that a single amino acid 
substitution of serine 358 to leucine (S358L) in LUMA is the unequivocal cause of fully penetrant 
arrhythmogenic right ventricular cardiomyopathy (ARVC), characterized by ventricular 
tachycardia, fibro-fatty replacement of cardiomyocytes, heart failure, and sudden cardiac death 
2, 33-36. It has also been reported that mutations in Luma are associated with Emery Dreifuss 
Muscular Dystrophy (EDMD)-related myopathy 4.  
 
Although there are several in vitro studies in cultured cardiomyocytes and non-cardiomyocytes 
addressing potential roles of Luma and effects of the S358L mutation35, 37-39, no studies have 
addressed the role of Luma during cardiac development and function in vivo. There are also no 
in vivo studies to address molecular mechanisms by which the LUMA S358L mutation leads to 
cardiomyopathy in animal models. To investigate the in vivo role of Luma in mammalian heart, 
we first determined the expression pattern of Luma in mouse heart. We found that Luma was 
sporadically expressed in cardiomyocytes, but was highly and uniformly expressed in cardiac 
fibroblasts and vascular smooth muscle cells. As Luma was expressed in most cell types in the 
heart, we took a global knockout (KO) approach to study effects of Luma loss on cardiac 
function. Echocardiography of Luma KO mice revealed no defects in cardiac function up to 20 
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months of age, and Luma KO mice responded normally to pressure overload induced by 
transverse aortic constriction (TAC). Furthermore, hemodynamic analysis revealed that Luma 
KOs had normal contractile function in response to treatment with the beta-1 agonist 
dobutamine. Given these data, we hypothesized that the S358L mutation was likely a gain-of-
function mutation. Therefore, we generated S358L knock-in (KI) mice using a CRISPR/Cas9 
approach to ensure that the gene encoding the S358L mutant Luma would be expressed under 
the control of the endogenous Luma locus. Luma KI mice displayed normal cardiac function at 
baseline. Taken together, our data suggest that Luma is dispensable for murine cardiac 
development and function, and that the Luma S358L mutation alone may not cause 
cardiomyopathy in mice.  
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Materials and Methods 
Study approval 
All animal procedures were approved by the UCSD Animal Care and Use Committee and were 
in full compliance with the guidelines for the care and use of laboratory animals from the 
National Institutes of Health. UCSD has an Animal Welfare Assurance (A3033-01) on file with 
the Office of Laboratory Animal Welfare and is fully accredited by AAALAC International.  
For isolation of adult hearts, mice were sacrificed by cervical dislocation following anaesthesia 
by intraperitoneal injection of a mixture of ketamine (100 mg/kg) and xylazine (5 mg/kg), while 
the depth of anaesthesia was monitored by toe pinch. For isolation of neonatal cardiomyocytes, 
neonatal mice were sacrificed by decapitation. 
 
Generation of Luma global knockout  (KO) and S358L knockin (KI) Mice. 
Embryonic stem cells containing the Tmem43tm1a(EUCOMM)Wtsi  knockout first construct were 
obtained from the IMPC Consortium, injected into blastocysts and implanted in pseudo-pregnant 
female mice as previously described (S Fig 3A) 40. Chimeric Luma floxed (Lumaf/+) mice were 
crossed with Sox2-Cre deleter mice to obtain Luma +/- mice 41. 
 
Luma KI mice were generated by using a CRISPR/Cas9 approach 42. Briefly, CRISPR RNA 
(crRNA), trans-activating crRNA (tracrRNA), Cas9 protein were injected along with the donor 
oligonucleotide into C57/B6J mouse zygotes, which were designed to replace TCC (Serine) with 
TTA (Leucine) (S Fig 4A-D). Genotyping by PCR analyses confirmed the presence of the 
mutant allele (S Fig 4C). 2 founder heterozygous knockin mice were crossed for 3 generations 
into C57/B6J to dilute any potential off-target effects.  
 
Echocardiography, Hemodynamics, and Transverse Aortic Constriction 
Mice were anesthetized with 0.5% isoflurane and underwent echocardiography using 
VisualSonics, SonoSite FUJIFILM, Vevo 2100 ultrasound system with a linear transducer 32-
55MHz as described previously 40, 43, 44. Measurements of heart rate (HR), left ventricular 
internal dimension at end of diastole and systole (LVIDd, LVIDs, respectively), end-diastolic 
interventricular septal thickness (IVSd) and LV posterior wall thickness (LVPWd) were 
determined from the LV M-mode tracing. Percentage fractional shortening (%FS) was used as 
an indicator of systolic cardiac function. For hemodynamics, 10 week old adult mice were 
anesthetized using 100mg/kg ketamine and 10 mg/kg xylazine and subjected to hemodynamic 
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measurements as described previously 40. N=8 mice were used for each genotype. For 
Transverse Aortic Constriction (TAC) 10 week-old male mice weighing 20-28g were 
anaesthetized with ketamine/ xylazine and aortas banded with a 27.5 gauge (for <25 g mice) or 
27 gauge (for mice ≥25 g) needle as previously described 45.  
 
Immunofluorescence 
Hearts from Collagen1a1-GFP, Tbx18-H2B-GFP and HCN4-tdTomato expressing mice were 
perfusion fixed with 4% PFA or ice-cold acetone, respectively, and dehydrated using sucrose 
gradients followed by embedding in a sucrose/ optical cutting temperature (OCT) mix as 
previously described 46. All other hearts were isolated and rinsed in PBS, immersed in cold 
isopentane and embedded in OCT on dry ice. Unfixed sections (10μm) were cut and fixed in 
acetone at -20°C for 5 mins. After permeabilization with washing buffer (PBS with 0.2% TX-100) 
sections were incubated with the indicated antibodies (Supplementary Table 1) overnight in 
blocking buffer (PBS with 2% normal donkey serum, 3% BSA) in a humidified chamber at 4°C. 
Sections were rinsed in wash buffer and incubated at room temperature with the indicated 
fluorescently-conjugated secondary antibodies and DAPI (1:500) diluted in blocking buffer for 
1h. Slides were rinsed in wash buffer and mounted in mounting buffer (Dako). Sections were 
imaged as described previously 47-49. Briefly, using an oil-immersed 100X objective, with 1.35 
numerical aperture, on an inverted microscope controlled by a DeltaVision system (Applied 
Precision, Washington, USA). 
 
Western blotting 
Ventricles were lysed in 50 μL/mg tissue as described previously 48. Briefly, frozen heart tissue 
and lysis buffer was pulverized in to a fine powder using a pestle and mortar, followed by 
sonication to shear DNA. Lysates were centrifuged at 13,900g at 4°C for 15 mins, supernatants 
aspirated and loaded on to 4-12% NuPage Bis/Tris gels for separation before transfer on to a 
Nitrocellulose membrane (Biorad) at 4°C at a constant voltage of 55V in transfer buffer (25 mM 
Tris, 190 mM Glycine, 20% Methanol, pH 8.3). After blocking for 1-2 hours in Tris Buffered 
Saline containing 0.1% Tween 20 and 5% non-fat dry milk, membranes were incubated 
overnight at 4°C with the indicated primary antibody (Supplementary Table 1) in blocking buffer. 
Blots were washed and incubated with horseradish peroxidase-conjugated secondary antibody 
for 1 hour at room temperature. Immunoreactive protein bands were visualized using enhanced 
chemiluminescence reagent (Thermo). 
 
CVR-2017-635 
 7 
Primary Cell Isolations 
Neonatal cardiomyocytes were isolated from postnatal day 1-2 pups using a combination of 
Trypsin and Collagenase Type II enzymes as described previously 50. Briefly, hearts were 
isolated, rinsed in PBS and incubated overnight with trypsin at 4°C. The next day hearts were 
digested with warm trypsin followed by 2 collagenase type II treatments. Cells were then pre-
plated to remove fibroblasts and other cell types, and the floating cardiomyocytes aspirated, 
counted and seeded on to Laminin-coated glass-bottomed Mattek dishes. Fibroblasts were 
trypsinised, counted and plated on Mattek dishes. 
 
Scratch Wound assays 
Isolated fibroblasts were counted and seeded onto 35mm plastic dishes. A sterile scratch was 
made using a P200 tip, detached cells were rinsed with medium and phase contrast images 
were recorded every 3 hours using an Olympus Analogue Video Camera System mounted on a 
Nikon TMS microscope. Image analysis was performed by tracing the edge of the wound using 
Image J and the remaining wound was calculated using Microsoft Excel. 
 
Histology 
Hearts were isolated from age and sex matched littermates and washed in PBS before being 
fixed overnight in Formalin. Hearts were subsequently dehydrated in 70% Ethanol and 
embedded in paraffin and cut into 10 μm sections. Sections were stained using Masson’s 
Trichrome, mounted and imaged using a Hamamatsu NanoZoomer 2.0HT Slide Scanning 
System (Hamamatsu) as described previously 51. 
 
Real-time PCR 
Total RNA was extracted from mouse hearts using Trizol reagent according to manufacturer’s 
recommendations (Life Technologies). cDNA was synthesized using MMLV Reverse 
Transcriptase (Bio-Rad). Primers for RT-PCR are listed in Supplementary Table 2. RT-PCR 
reactions were performed using Sso-Fast EvaGreen Real Time PCR (Bio-Rad) master mix in 
96-well low profile PCR plates in the CFX96 Biorad Thermocycler.  
 
Human tissues 
Human specimens were obtained from the Sydney Heart Bank at the University of Sydney and 
signed patient consent was obtained for all samples in this tissue bank. Human Research Ethics 
Committee approval was obtained by St Vincent’s Hospital (#H03/118), and by the University of 
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Sydney Human Research Ethics Committee (#12146, #159401) and conforms to the principles 
in the Declaration of Helsinki. Human tissue was used in accordance with the ethical guidelines 
of King’s College London (College Research Ethical Committee 04/05–74; REC reference 
12/EM/0106), under current UK law. Samples from the left ventricular free walls of patients from 
non-failing donor hearts, which were cardiopleged, but not required for heart transplantation, 
were provided by the Australian Red Cross Blood Transfusion Service. Typically these hearts 
were not transplanted because of tissue incompatibility. 
 
Statistics 
Data are presented as mean ± standard error of the mean (SEM) unless indicated otherwise. 
We used 2-tailed Student’s t test or 2-way ANOVA, with Sadik’s post-hoc test for comparisons 
among groups as indicated. Analysis was performed using Microsoft Excel or Graphpad Prism 
software. P values of less than 0.05 were considered significant.  
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Results 
Luma is expressed in most cell types, predominantly in fibroblasts and coronary 
vascular smooth muscle cells in mouse and human myocardium, 
Luma mRNA and protein are expressed in human hearts 2, 33. We first confirmed expression of 
Luma in mouse hearts, as well as skeletal muscle, and a number of other tissues by Western 
blot analysis (S Fig 1A). Although widely expressed, Luma was abundantly expressed in heart 
(S Fig 1A). To investigate Luma subcellular localization and expression within various cell types 
of the heart, we next performed immunofluorescence microscopy utilizing a panel of antibodies 
and various green fluorescent protein (GFP) and tdTomato indicator mouse lines (Figs 1A-G). 
Whereas Luma was localized to the nuclear envelope in 71% of cardiomyocytes  (Obscurin-
H2B-GFP 52, 53, Fig 1A), it was expressed in all cardiac fibroblasts of all four chambers of heart 
(PDGFR-alpha, Fig 1B and Collagen-1a1-GFP 52, 53, Fig 1C and S Fig 1B). Immunofluorescence 
analysis of Luma in vascular smooth muscle cells (vSMCs; alpha smooth muscle actin, Fig 1D), 
endothelial cells (ECs; CD31, Fig 1E), and pericytes (Tbx18-H2B-GFP 54, Fig 1F), revealed high 
expression in vSMCs, whereas Luma was rarely observed in endothelial cells, and only in some 
pericytes. Because mutations in Luma lead to fatal arrhythmias in humans 2, 33, we predicted 
that Luma might be enriched in regions of the heart responsible for cardiac conduction. To test 
this hypothesis, we used the HCN4CreERT2-tdTomato indicator line to mark the cardiac 
conduction system 55. However, Luma was not observed in the sino-atrial node, atrio-ventricular 
node or Purkinje fibers (Fig 1G and data not shown).  
 
Consistent with the expression pattern of Luma in mouse myocardium, immunofluorescence 
staining of human myocardium obtained from the left ventricle of non-failing adults revealed 
that, as in mouse heart, Luma concentrated at the nuclear envelope and was predominantly 
found in vascular smooth muscle cells and cardiac interstitial cells (S Fig 2). 
 
Luma knockout mice are viable and have normal cardiac function and morphology 
To investigate the in vivo role of Luma in cardiac function, we generated Luma knockout (KO) 
mice by crossing targeted mice containing Luma floxed alleles with global deleter Sox2-cre mice 
41 (S Figs 3A-B). Luma KO mice were born at expected Mendelian ratios with 48 out of an 
expected 50 pups (from 202 pups total) observed from Luma heterozygous null crosses (S Fig 
3C). Western blotting and immunofluorescence analyses confirmed loss of Luma expression in 
KO mice (S Figs 3D-F). Given this result, we next evaluated cardiac function of Luma KO and 
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wildtype mice over the course of 20 months by echocardiography (Fig 2 A-E). Cardiac function 
of Luma KO mice was comparable to wildtype littermates (32% vs. 35% Fractional Shortening), 
as were Left Ventricle Internal Dimensions in diastole (LVIDd, both 3.9mm) and systole (LVIDs, 
2.6mm vs. 2.5mm), Left Ventricle Posterior Wall thickness in diastole (LVPWd, 0.79mm vs. 
0.72mm), and Inter-Ventricular Septum thickness in diastole (IVSd, 0.83mm vs. 0.81mm) at 88 
weeks (Figs 2A-E). We observed no changes in any of these parameters, irrespective of their 
gender. We also observed no change in expression levels of the fetal gene program (ANP, 
BNP, Myh6, Myh7) and pro-fibrotic markers (Collagen 1a1 and 3a1) by qRT-PCR analysis (Fig 
2F). Complementary to the echocardiography and gene expression analyses, Hematoxylin & 
Eosin staining revealed no evidence of morphological defects (Fig 2G). There were also no 
changes in heart weight to body weight and heart weight to tibia length ratios of Luma KO mice 
when compared to wildtype littermates (Fig 2H). 
 
Localization of most LINC complex proteins and nuclear Lamins are unaffected in Luma 
knockout cardiomyocytes and fibroblasts 
Since ablation of other LINC complex proteins has been shown to affect LINC complex integrity 
18, 48, we hypothesized that known interaction partners of Luma may be compensating for loss of 
Luma in Luma KO mice. Western blot analysis revealed that levels of Lamins A/C, B1, Sun2, 
and Emerin were unchanged in Luma KO versus wildtype mice at 88 weeks (Fig 3A, S Fig 3G). 
Given that Luma binds to LINC complex-associated proteins Lamin A/C, B1, Emerin, and SUN2 
1, 4, and knockdown of Luma in HeLa cells led to mislocalization of Emerin 1, we isolated both 
cardiomyocytes and cardiac fibroblasts from wildtype and Luma KO neonatal hearts and 
performed immunostaining for various LINC complex and LINC complex-associated 
components. As expected, Luma localized to the nuclear envelope in cardiomyocytes (Figs 1A 
and 3B) and fibroblasts (Fig 1B). Localization of Lamins A/C, B1, Emerin, Sun1, and Sun2 were 
unchanged between wildtype and Luma KO in both cell types, where they localized to the 
nuclear envelope (Figs 3 C-D). Isolation and staining of adult cardiomyocytes from wildtype and 
Luma KO mice showed similar localization of the LINC components (data not shown). Because 
Luma was expressed at high levels in fibroblasts, and the LINC complex has been implicated in 
cell migration 56, 57, we hypothesized that Luma KO fibroblasts might display migration defects. 
To test this, we performed scratch-wound assays, but observed that Luma KO fibroblasts were 
able to migrate at the same rate as wildtype fibroblasts (Fig 3E). 
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Luma knockout mice exhibit normal hypertrophic response to pressure overload  
Lamin A/C heterozygous null mice display an attenuated hypertrophic response following 
pressure overload by transverse aortic constriction (TAC) 58. Given that Luma interacts with 
Lamin A/C, and that LINC complex components have been shown to play both structural and 
mechanotransduction roles 18-21, we hypothesized that Luma KO mice may also display an 
attenuated hypertrophic response to pressure overload. To test this hypothesis, we performed 
TAC on 10 week-old mice followed by serial echocardiography measurements at 1 and 2 
weeks, post-TAC. As expected, when compared to SHAM-operated animals, wildtype mice 
subjected to TAC underwent remodeling, as evidenced by a progressive decrease in cardiac 
function, and increasing dimensions of the left ventricular chambers and wall thickness (Figs 
4A-E). However, there were no significant differences in any of these parameters between 
Luma KO and wildtype littermates (P>0.05, 2-way ANOVA), suggesting that Luma KO hearts 
exhibit a normal hypertrophic response to pressure overload. At 4 weeks post-TAC, both 
wildtype and Luma KO mice progressed to heart failure, with comparable Fractional Shortening 
(mean values 19.5% and 21.3%, respectively); chamber sizes, LVIDd (4.1mm and 3.8mm, 
respectively), LVIDs (3.4mm and 3.1mm, respectively); wall thicknesses, LVPWd (1.0mm and 
1.1mm, respectively), IVSd (both 1.0mm); with no significant differences observed (P>0.05, 2-
way ANOVA) (Figs 4A-E). Furthermore, Kaplan-Meier survival analysis found no significant 
difference between Luma KO and wildtype littermates post-TAC (median survivals of 52 and 62 
days, respectively, P=0.87, Mantel-Cox Chi Square test) (Fig 4F). Western blot analysis 
detected no difference in expression levels of binding partners of Luma (Fig 4G, S Fig 3H). 
 
Contractile function of Luma knockout mice is unaffected in response to beta-adrenergic 
stimulation 
Given that Luma KO mice showed normal cardiac function at 88 weeks of age, and had similar 
hypertrophic response and heart failure progression as their control littermates following TAC, 
we next investigated cardiac contractile function following beta-adrenergic stimulation. Ten-
week-old mice were treated with increasing amounts of dobutamine and subjected to 
hemodynamic analyses. Results demonstrated that Luma KO mice responded similarly to 
wildtype littermates, with no impairment of contractile function in response to beta-adrenergic 
stimulation (Figs 5A-F). Taken together, Luma KO mice displayed no overt cardiac defects, 
responded normally to pressure overload, and had normal contractile function.  
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Luma S358L knock-in mice have normal cardiac function 
Given that no changes in cardiac function were observed following global loss of Luma, we 
reasoned that the S358L mutation in Luma that causes ARVC in humans might be a gain-of-
function mutation. To test whether the Luma S358L mutation is a gain-of-function mutation, we 
generated knock-in mice using a CRISPR/Cas9 approach (S Fig 4A-D). Two founder 
heterozygous mutant mice were crossed for 3 generations into a C57B6J background to dilute 
potential off-target effects. Heterozygous mutants were then interbred to produce homozygous 
S358L mutants. From 154 pups analyzed, 72 homozygous (expected 77) and 35 heterozygous 
(expected 38.5) mutants were present at weaning, suggesting that homozygous null mutants 
were present at expected Mendelian ratios (Chi squared test, p=0.28) (S Fig 4E). 
 
After generating S358L mice, we performed echocardiography over the course of 12 months on 
the S358L mutants. Surprisingly, we observed no changes between S358L heterozygous, 
homozygous, and wildtype littermates in cardiac function (FS, 41%, 40%, 37%, respectively); 
LVIDd (3.0mm, 3.1mm, 3.1mm, respectively); LVIDs (1.8mm, 1.8mm, 2.0mm, respectively);  
LVPWd (0.79mm, 0.79mm, 0.72mm, respectively); IVSd (0.85mm, 0.83mm, 0.79mm, 
respectively) at 1 year of age (Fig 6A-E). Next, we checked expression levels of fetal genes 
ANP, BNP, Myh6, Myh7) and pro-fibrotic genes (Collagen-1a1, Collagen-3a1) in 2-3 month-old 
mice. Consistent with our echocardiographic analysis, we observed no changes in these factors, 
which suggested an absence of remodeling in mutants (Fig 6F). The indices of hypertrophy 
(HW:BW and HW:TL ratios) were unchanged between wildtype and S358L mutant mice (Fig 
6G). Consistent with the lack of an ARVC-like phenotype, we observed no incidences of sudden 
death or premature lethality of S358L mutant mice compared to their wildtype littermates. 
 
Luma S358L mutant localizes normally to the nuclear envelope in Luma S358L mutant 
myocardium and levels of LINC proteins are unchanged in Luma S358L mutant cardiac 
tissue 
The mutant S358L Luma protein has been reported to have an altered subcellular localization in 
HL1 cells, where it localizes to microfilaments and structures resembling phagosomes 38. 
However, the subcellular localization of the Luma S358L mutant in heart has not been 
investigated when expressed under the control of the endogenous Luma locus. We found that 
the mutant S358L Luma protein localized to the nuclear envelope as was observed for wildtype 
Luma (Fig 6H). Previously, it was reported that Luma staining in human myocardium was 
reduced in patients with S358L mutations 33, however we found that Luma levels were similar in 
CVR-2017-635 
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wildtype and both S358L heterozygous and homozygous mice (Fig 6I). In vivo analysis of 
S358L mutant mouse hearts suggested cardiac function was normal and that Luma localization 
was unaffected. Next we checked the levels of binding partners of Luma to investigate any 
potential alterations in expression levels of these proteins. As with Luma KO mice, levels of 
Lamins A/C, B1, Emerin, and SUN2 were unchanged in S358L mutant mice when compared to 
those in wildtype littermates (Fig 6J).  
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Discussion 
Luma is an INM protein associated with the LINC complex 1 and is highly expressed in heart 2 
(and this study). Previous human genetic linkage studies have revealed that an autosomal-
dominant S358L mutation in Luma is the unequivocal cause of fully penetrant ARVC 2, 33-35. To 
investigate the role Luma in mammalian heart, we determined the expression pattern of Luma in 
mouse heart, using an antibody that had been validated by comparing western blot and 
immunostaining signals in wildtype and Luma null hearts. We found that Luma was sporadically 
expressed in cardiomyocytes, but was highly and uniformly expressed in cardiac fibroblasts and 
vascular smooth muscle cells in both mouse and human myocardium. We then confirmed that 
Luma was selectively expressed at the nuclear envelope in cardiomyocytes and cardiac 
fibroblasts. Localization and expression of other LINC complex components was unaffected in 
Luma KO hearts and cardiac myocytes. Furthermore, we found that Luma was expressed in the 
same cell types in human myocardium. Interestingly, others have reported that Luma localizes 
to the sarcolemma and intercalated disc in human and pig hearts 33, 39. However, whether these 
antibodies recognize Luma, or a protein with a similar epitope to Luma that resides at these 
structures remains to be seen. 
 
We then generated and characterized Luma KO mice. Surprisingly, Luma null mice were viable 
and displayed no defects in cardiac function, even at 2 years of age. In addition, Luma KO mice 
responded normally to pressure overload induced by transverse aortic constriction. 
Explanations as to why no cardiac phenotype was observed in global Luma KO mice include: 1) 
Luma KO mice were generated in an inbred C57B6 background, which may lack certain genetic 
modifiers required to exacerbate phenotypes associated with alterations in Luma function. Mice 
of a different strain may more closely model the human phenotype; 2) Function of Luma in 
humans or mice may not be equivalent. This was shown to be the case for the LINC-associated 
component Emerin. X-linked EDMD in humans, caused by ablation or reduction of Emerin 
expression by a mutation that leads to a premature stop codon, was not recapitulated in Emerin 
KO mice, which displayed relatively mild phenotypes compared to X-EDMD patients. Only when 
both Emerin and its interaction partner LAP1 were ablated was a significant phenotype 
observed in mice. In this regard, it is should be pointed out that there is no report to show that 
Luma nonsense mutations in human result in cardiomyopathy.  
 
Given that no changes in cardiac function were observed following global loss of Luma, we 
reasoned that the S358L mutation in Luma that causes ARVC in human might be a gain-of-
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function mutation. To test whether the Luma S358L mutation is a gain-of-function mutation, we 
generated and characterized Luma knock-in mice. We found that Luma S358L knock-in mice 
had normal cardiac function, that Luma S358L mutant protein localized normally to the nuclear 
envelope, and that levels of LINC proteins were unchanged in Luma S358L mutant cardiac 
tissue. Our observation of no baseline cardiac phenotype in Luma KI mice was quite 
unexpected, given that human genetic linkage studies have unequivocally revealed that the 
S358L mutation in Luma results in cardiomyopathy 2, 33. In addition, human and mouse 
orthologues of Luma share 93% identity and the serine 358 residue and adjacent region is 
100% conserved between human and mouse 1 . However, it should be pointed out that many 
patients with the S358L mutation develop late-onset cardiomyopathy2. We only measured 
cardiac function of Luma KI mice, which were in a pure C57/B6 genetic background, at baseline 
conditions up to 12 months of age. Future studies are needed to determine whether Luma 
S358L KI mice in C67/B6 or other genetic backgrounds would eventually develop 
cardiomyopathy with greater age, and to determine whether Luma S358L KI mice respond 
normally to cardiac stress, such as TAC-induced pressure overload.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CVR-2017-635 
 16 
Funding information 
MJS, XF were supported by AHA postdoctoral fellowships (13POST17060120, 
16POST30960067). JV was supported by a CIRM postdoctoral fellowship (TG2-01154). JC and 
SME were funded by grants from the National Institutes of Health. JC was also funded by 
Foundation Leducq (TNE-13CVD04) and is the American Heart Association Endowed Chair in 
Cardiovascular Research. Microscopy was supported by NIH grant P30 NS047101.  
 
Acknowledgements 
We would like to thank Cris dos Remedios (University of Sydney) and Elisabeth Ehler (King’s 
College London) for kindly providing the non-failing human heart samples. 
 
Conflict of Interest 
None declared 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CVR-2017-635 
 17 
References 
1. Bengtsson L, Otto H. LUMA interacts with emerin and influences its distribution at the 
inner nuclear membrane. J Cell Sci 2008;121:536-548. 
2. Merner ND, Hodgkinson KA, Haywood AF, Connors S, French VM, Drenckhahn JD, 
Kupprion C, Ramadanova K, Thierfelder L, McKenna W, Gallagher B, Morris-Larkin L, 
Bassett AS, Parfrey PS, Young TL. Arrhythmogenic right ventricular cardiomyopathy 
type 5 is a fully penetrant, lethal arrhythmic disorder caused by a missense mutation in 
the TMEM43 gene. Am J Hum Genet 2008;82:809-821. 
3. Dreger M, Bengtsson L, Schoneberg T, Otto H, Hucho F. Nuclear envelope proteomics: 
novel integral membrane proteins of the inner nuclear membrane. Proc Natl Acad Sci U 
S A 2001;98:11943-11948. 
4. Liang WC, Mitsuhashi H, Keduka E, Nonaka I, Noguchi S, Nishino I, Hayashi YK. 
TMEM43 mutations in Emery-Dreifuss muscular dystrophy-related myopathy. Ann 
Neurol 2011;69:1005-1013. 
5. Stroud MJ, Banerjee I, Veevers J, Chen J. Linker of nucleoskeleton and cytoskeleton 
complex proteins in cardiac structure, function, and disease. Circ Res 2014;114:538-
548. 
6. Schirmer EC, Florens L, Guan T, Yates JR, 3rd, Gerace L. Nuclear membrane proteins 
with potential disease links found by subtractive proteomics. Science 2003;301:1380-
1382. 
7. Sosa BA, Rothballer A, Kutay U, Schwartz TU. LINC complexes form by binding of three 
KASH peptides to domain interfaces of trimeric SUN proteins. Cell 2012;149:1035-1047. 
8. Crisp M, Liu Q, Roux K, Rattner JB, Shanahan C, Burke B, Stahl PD, Hodzic D. 
Coupling of the nucleus and cytoplasm: role of the LINC complex. J Cell Biol 
2006;172:41-53. 
9. Haque F, Lloyd DJ, Smallwood DT, Dent CL, Shanahan CM, Fry AM, Trembath RC, 
Shackleton S. SUN1 interacts with nuclear lamin A and cytoplasmic nesprins to provide 
a physical connection between the nuclear lamina and the cytoskeleton. Mol Cell Biol 
2006;26:3738-3751. 
10. Padmakumar VC, Libotte T, Lu W, Zaim H, Abraham S, Noegel AA, Gotzmann J, 
Foisner R, Karakesisoglou I. The inner nuclear membrane protein Sun1 mediates the 
anchorage of Nesprin-2 to the nuclear envelope. J Cell Sci 2005;118:3419-3430. 
11. Starr DA, Han M. Role of ANC-1 in tethering nuclei to the actin cytoskeleton. Science 
2002;298:406-409. 
12. Starr DA, Fridolfsson HN. Interactions between nuclei and the cytoskeleton are mediated 
by SUN-KASH nuclear-envelope bridges. Annu Rev Cell Dev Biol 2010;26:421-444. 
13. Jaalouk DE, Lammerding J. Mechanotransduction gone awry. Nat Rev Mol Cell Biol 
2009;10:63-73. 
14. Lombardi ML, Lammerding J. Keeping the LINC: the importance of nucleocytoskeletal 
coupling in intracellular force transmission and cellular function. Biochem Soc Trans 
2011;39:1729-1734. 
15. Mammoto A, Mammoto T, Ingber DE. Mechanosensitive mechanisms in transcriptional 
regulation. J Cell Sci 2012;125:3061-3073. 
16. Puckelwartz MJ, Depreux FF, McNally EM. Gene expression, chromosome position and 
lamin A/C mutations. Nucleus 2011;2:162-167. 
17. Wang N, Tytell JD, Ingber DE. Mechanotransduction at a distance: mechanically 
coupling the extracellular matrix with the nucleus. Nat Rev Mol Cell Biol 2009;10:75-82. 
18. Banerjee I, Zhang J, Moore-Morris T, Pfeiffer E, Buchholz KS, Liu A, Ouyang K, Stroud 
MJ, Gerace L, Evans SM, McCulloch A, Chen J. Targeted ablation of nesprin 1 and 
nesprin 2 from murine myocardium results in cardiomyopathy, altered nuclear 
CVR-2017-635 
 18 
morphology and inhibition of the biomechanical gene response. PLoS Genet 
2014;10:e1004114. 
19. Ho CY, Jaalouk DE, Vartiainen MK, Lammerding J. Lamin A/C and emerin regulate 
MKL1-SRF activity by modulating actin dynamics. Nature 2013;497:507-511. 
20. Lammerding J, Hsiao J, Schulze PC, Kozlov S, Stewart CL, Lee RT. Abnormal nuclear 
shape and impaired mechanotransduction in emerin-deficient cells. J Cell Biol 
2005;170:781-791. 
21. Lammerding J, Schulze PC, Takahashi T, Kozlov S, Sullivan T, Kamm RD, Stewart CL, 
Lee RT. Lamin A/C deficiency causes defective nuclear mechanics and 
mechanotransduction. J Clin Invest 2004;113:370-378. 
22. Puckelwartz MJ, Kessler EJ, Kim G, Dewitt MM, Zhang Y, Earley JU, Depreux FF, 
Holaska J, Mewborn SK, Pytel P, McNally EM. Nesprin-1 mutations in human and 
murine cardiomyopathy. J Mol Cell Cardiol 2010;48:600-608. 
23. Zhang J, Felder A, Liu Y, Guo LT, Lange S, Dalton ND, Gu Y, Peterson KL, Mizisin AP, 
Shelton GD, Lieber RL, Chen J. Nesprin 1 is critical for nuclear positioning and 
anchorage. Hum Mol Genet 2010;19:329-341. 
24. Bione S, Maestrini E, Rivella S, Mancini M, Regis S, Romeo G, Toniolo D. Identification 
of a novel X-linked gene responsible for Emery-Dreifuss muscular dystrophy. Nat Genet 
1994;8:323-327. 
25. Bonne G, Di Barletta MR, Varnous S, Becane HM, Hammouda EH, Merlini L, Muntoni F, 
Greenberg CR, Gary F, Urtizberea JA, Duboc D, Fardeau M, Toniolo D, Schwartz K. 
Mutations in the gene encoding lamin A/C cause autosomal dominant Emery-Dreifuss 
muscular dystrophy. Nat Genet 1999;21:285-288. 
26. Mounkes LC, Kozlov SV, Rottman JN, Stewart CL. Expression of an LMNA-N195K 
variant of A-type lamins results in cardiac conduction defects and death in mice. Hum 
Mol Genet 2005;14:2167-2180. 
27. Arimura T, Helbling-Leclerc A, Massart C, Varnous S, Niel F, Lacene E, Fromes Y, 
Toussaint M, Mura AM, Keller DI, Amthor H, Isnard R, Malissen M, Schwartz K, Bonne 
G. Mouse model carrying H222P-Lmna mutation develops muscular dystrophy and 
dilated cardiomyopathy similar to human striated muscle laminopathies. Hum Mol Genet 
2005;14:155-169. 
28. Fatkin D, MacRae C, Sasaki T, Wolff MR, Porcu M, Frenneaux M, Atherton J, Vidaillet 
HJ, Jr., Spudich S, De Girolami U, Seidman JG, Seidman C, Muntoni F, Muehle G, 
Johnson W, McDonough B. Missense mutations in the rod domain of the lamin A/C gene 
as causes of dilated cardiomyopathy and conduction-system disease. N Engl J Med 
1999;341:1715-1724. 
29. Taylor MR, Slavov D, Gajewski A, Vlcek S, Ku L, Fain PR, Carniel E, Di Lenarda A, 
Sinagra G, Boucek MM, Cavanaugh J, Graw SL, Ruegg P, Feiger J, Zhu X, Ferguson 
DA, Bristow MR, Gotzmann J, Foisner R, Mestroni L, Familial Cardiomyopathy Registry 
Research G. Thymopoietin (lamina-associated polypeptide 2) gene mutation associated 
with dilated cardiomyopathy. Hum Mutat 2005;26:566-574. 
30. Zhang Q, Bethmann C, Worth NF, Davies JD, Wasner C, Feuer A, Ragnauth CD, Yi Q, 
Mellad JA, Warren DT, Wheeler MA, Ellis JA, Skepper JN, Vorgerd M, Schlotter-Weigel 
B, Weissberg PL, Roberts RG, Wehnert M, Shanahan CM. Nesprin-1 and -2 are 
involved in the pathogenesis of Emery Dreifuss muscular dystrophy and are critical for 
nuclear envelope integrity. Hum Mol Genet 2007;16:2816-2833. 
31. Mejat A, Misteli T. LINC complexes in health and disease. Nucleus 2010;1:40-52. 
32. Puckelwartz MJ, Kessler E, Zhang Y, Hodzic D, Randles KN, Morris G, Earley JU, 
Hadhazy M, Holaska JM, Mewborn SK, Pytel P, McNally EM. Disruption of nesprin-1 
produces an Emery Dreifuss muscular dystrophy-like phenotype in mice. Hum Mol 
Genet 2009;18:607-620. 
CVR-2017-635 
 19 
33. Christensen AH, Andersen CB, Tybjaerg-Hansen A, Haunso S, Svendsen JH. Mutation 
analysis and evaluation of the cardiac localization of TMEM43 in arrhythmogenic right 
ventricular cardiomyopathy. Clin Genet 2011;80:256-264. 
34. Hodgkinson KA, Connors SP, Merner N, Haywood A, Young TL, McKenna WJ, 
Gallagher B, Curtis F, Bassett AS, Parfrey PS. The natural history of a genetic subtype 
of arrhythmogenic right ventricular cardiomyopathy caused by a p.S358L mutation in 
TMEM43. Clin Genet 2013;83:321-331. 
35. Rajkumar R, Sembrat JC, McDonough B, Seidman CE, Ahmad F. Functional effects of 
the TMEM43 Ser358Leu mutation in the pathogenesis of arrhythmogenic right 
ventricular cardiomyopathy. BMC Med Genet 2012;13:21. 
36. Milting H, Klauke B, Christensen AH, Musebeck J, Walhorn V, Grannemann S, Munnich 
T, Saric T, Rasmussen TB, Jensen HK, Mogensen J, Baecker C, Romaker E, Laser KT, 
zu Knyphausen E, Kassner A, Gummert J, Judge DP, Connors S, Hodgkinson K, Young 
TL, van der Zwaag PA, van Tintelen JP, Anselmetti D. The TMEM43 Newfoundland 
mutation p.S358L causing ARVC-5 was imported from Europe and increases the 
stiffness of the cell nucleus. Eur Heart J 2015;36:872-881. 
37. Jiang C, Zhu Y, Zhou Z, Gumin J, Bengtsson L, Wu W, Songyang Z, Lang FF, Lin X. 
TMEM43/LUMA is a key signaling component mediating EGFR-induced NF-kappaB 
activation and tumor progression. Oncogene 2017;36:2813-2823. 
38. Siragam V, Cui X, Masse S, Ackerley C, Aafaqi S, Strandberg L, Tropak M, Fridman 
MD, Nanthakumar K, Liu J, Sun Y, Su B, Wang C, Liu X, Yan Y, Mendlowitz A, Hamilton 
RM. TMEM43 mutation p.S358L alters intercalated disc protein expression and reduces 
conduction velocity in arrhythmogenic right ventricular cardiomyopathy. PLoS One 
2014;9:e109128. 
39. Franke WW, Dorflinger Y, Kuhn C, Zimbelmann R, Winter-Simanowski S, Frey N, Heid 
H. Protein LUMA is a cytoplasmic plaque constituent of various epithelial adherens 
junctions and composite junctions of myocardial intercalated disks: a unifying finding for 
cell biology and cardiology. Cell Tissue Res 2014;357:159-172. 
40. Zhang Z, Stroud MJ, Zhang J, Fang X, Ouyang K, Kimura K, Mu Y, Dalton ND, Gu Y, 
Bradford WH, Peterson KL, Cheng H, Zhou X, Chen J. Normalization of Naxos 
plakoglobin levels restores cardiac function in mice. J Clin Invest 2015;125:1708-1712. 
41. Hayashi S, Lewis P, Pevny L, McMahon AP. Efficient gene modulation in mouse epiblast 
using a Sox2Cre transgenic mouse strain. Mech Dev 2002;119 Suppl 1:S97-S101. 
42. Ma X, Chen C, Veevers J, Zhou X, Ross RS, Feng W, Chen J. CRISPR/Cas9-mediated 
gene manipulation to create single-amino-acid-substituted and floxed mice with a 
cloning-free method. Sci Rep 2017;7:42244. 
43. Sheikh F, Ouyang K, Campbell SG, Lyon RC, Chuang J, Fitzsimons D, Tangney J, 
Hidalgo CG, Chung CS, Cheng H, Dalton ND, Gu Y, Kasahara H, Ghassemian M, 
Omens JH, Peterson KL, Granzier HL, Moss RL, McCulloch AD, Chen J. Mouse and 
computational models link Mlc2v dephosphorylation to altered myosin kinetics in early 
cardiac disease. J Clin Invest 2012;122:1209-1221. 
44. Fang X, Bogomolovas J, Wu T, Zhang W, Liu C, Veevers J, Stroud MJ, Zhang Z, Ma X, 
Mu Y, Lao DH, Dalton ND, Gu Y, Wang C, Wang M, Liang Y, Lange S, Ouyang K, 
Peterson KL, Evans SM, Chen J. Loss-of-function mutations in co-chaperone BAG3 
destabilize small HSPs and cause cardiomyopathy. J Clin Invest 2017;127:3189-3200. 
45. Rockman HA, Ross RS, Harris AN, Knowlton KU, Steinhelper ME, Field LJ, Ross J, Jr., 
Chien KR. Segregation of atrial-specific and inducible expression of an atrial natriuretic 
factor transgene in an in vivo murine model of cardiac hypertrophy. Proc Natl Acad Sci U 
S A 1991;88:8277-8281. 
CVR-2017-635 
 20 
46. Boogerd CJ, Aneas I, Sakabe N, Dirschinger RJ, Cheng QJ, Zhou B, Chen J, Nobrega 
MA, Evans SM. Probing chromatin landscape reveals roles of endocardial TBX20 in 
septation. J Clin Invest 2016;126:3023-3035. 
47. Stroud MJ, Nazgiewicz A, McKenzie EA, Wang Y, Kammerer RA, Ballestrem C. GAS2-
like proteins mediate communication between microtubules and actin through 
interactions with end-binding proteins. J Cell Sci 2014;127:2672-2682. 
48. Stroud MJ, Feng W, Zhang J, Veevers J, Fang X, Gerace L, Chen J. Nesprin 1alpha2 is 
essential for mouse postnatal viability and nuclear positioning in skeletal muscle. J Cell 
Biol 2017;216:1915-1924. 
49. Stroud MJ, Kammerer RA, Ballestrem C. Characterization of G2L3 (GAS2-like 3), a new 
microtubule- and actin-binding protein related to spectraplakins. J Biol Chem 
2011;286:24987-24995. 
50. Fang X, Stroud MJ, Ouyang K, Fang L, Zhang J, Dalton ND, Gu Y, Wu T, Peterson KL, 
Huang HD, Chen J, Wang N. Adipocyte-specific loss of PPARgamma attenuates cardiac 
hypertrophy. JCI Insight 2016;1:e89908. 
51. Hirai M, Arita Y, McGlade CJ, Lee KF, Chen J, Evans SM. Adaptor proteins NUMB and 
NUMBL promote cell cycle withdrawal by targeting ERBB2 for degradation. J Clin Invest 
2017;127:569-582. 
52. Moore-Morris T, Guimaraes-Camboa N, Banerjee I, Zambon AC, Kisseleva T, 
Velayoudon A, Stallcup WB, Gu Y, Dalton ND, Cedenilla M, Gomez-Amaro R, Zhou B, 
Brenner DA, Peterson KL, Chen J, Evans SM. Resident fibroblast lineages mediate 
pressure overload-induced cardiac fibrosis. J Clin Invest 2014;124:2921-2934. 
53. Lange S, Ouyang K, Meyer G, Cui L, Cheng H, Lieber RL, Chen J. Obscurin determines 
the architecture of the longitudinal sarcoplasmic reticulum. J Cell Sci 2009;122:2640-
2650. 
54. Guimaraes-Camboa N, Cattaneo P, Sun Y, Moore-Morris T, Gu Y, Dalton ND, 
Rockenstein E, Masliah E, Peterson KL, Stallcup WB, Chen J, Evans SM. Pericytes of 
Multiple Organs Do Not Behave as Mesenchymal Stem Cells In Vivo. Cell Stem Cell 
2017;20:345-359 e345. 
55. Mezzano V, Liang Y, Wright AT, Lyon RC, Pfeiffer E, Song MY, Gu Y, Dalton ND, 
Scheinman M, Peterson KL, Evans SM, Fowler S, Cerrone M, McCulloch AD, Sheikh F. 
Desmosomal junctions are necessary for adult sinus node function. Cardiovasc Res 
2016;111:274-286. 
56. Luke Y, Zaim H, Karakesisoglou I, Jaeger VM, Sellin L, Lu W, Schneider M, Neumann S, 
Beijer A, Munck M, Padmakumar VC, Gloy J, Walz G, Noegel AA. Nesprin-2 Giant 
(NUANCE) maintains nuclear envelope architecture and composition in skin. J Cell Sci 
2008;121:1887-1898. 
57. Lee JS, Hale CM, Panorchan P, Khatau SB, George JP, Tseng Y, Stewart CL, Hodzic D, 
Wirtz D. Nuclear lamin A/C deficiency induces defects in cell mechanics, polarization, 
and migration. Biophys J 2007;93:2542-2552. 
58. Cupesi M, Yoshioka J, Gannon J, Kudinova A, Stewart CL, Lammerding J. Attenuated 
hypertrophic response to pressure overload in a lamin A/C haploinsufficiency mouse. J 
Mol Cell Cardiol 2010;48:1290-1297. 
 
 
 
 
 
CVR-2017-635 
 21 
Figure legends 
 
Figure 1: Luma is expressed in most cell types in the heart. Adult hearts from wildtype and 
various cell-type-specific indicator mouse lines were fixed and analyzed under 
immunofluorescence microscopy utilizing a panel of antibodies and various indicator mouse 
lines for various cell-type-specific markers (labeled as magenta/ red). (A) Obscurin-H2B-GFP 
(red) expressing mice were used to mark cardiomyocyte nuclei. Note that Luma was expressed 
in myocytes (white arrowheads). Inset, high magnification view of a cardiomyocyte nucleus 
expressing Luma. (B) Platelet Derived Growth Factor Receptor alpha (PDGFRα) to mark 
fibroblasts (red) and alpha-actinin (magenta). Inset, high magnification fibroblast nucleus in 
white box. (C) Collagen1a1-GFP (red, fibroblast marker). Note that Luma was expressed in all 
fibroblasts (yellow arrowheads), and some cardiomyocytes (white arrowheads). (D) Alpha 
smooth muscle actin (αSMA) was used to mark smooth muscle cells (magenta) and phalloidin 
for actin (red). Note that Luma was also expressed in smooth muscle cells (white arrows). (E) 
CD31 was used to mark endothelial cells (magenta). Note that Luma was found in some 
endothelial cells (white arrow). (F) Tbx18-H2B-GFP expressing hearts were used as a pericyte 
marker. Note that Luma was found in some pericytes (white arrows). (G) HCN4-tdTomato was 
used as a conduction system marker and the sinoatrial node (SAN) region was imaged. Note 
that Luma was not found in these cells (yellow arrows). DNA is stained with DAPI (blue). 
 
Figure 2: Luma KO mice display no overt defects in cardiac function and morphology. 
Echocardiographic measurements of (A) fractional shortening; (B) left ventricular (LV) internal 
diameter, diastole (LVIDd); (C) LV internal diameter, systole, (LVIDs); (D) LV posterior wall, 
diastole (LVPWd); and (E) interventricular septum diameter, diastole (IVSd) over the course of 
88 weeks in wildtype (WT) (n=13; 7 females, 6 males) and Luma knockout (KO) mice (n=14; 5 
females, 9 males). (F) Quantitative real-time PCR analysis of fetal genes ANP, BNP, Myh6, 
Myh7, and pro-fibrotic markers Collagen 1a1, and 3a1, in WT and Luma KO mouse hearts at 88 
weeks (n=7-9 per genotype). (G) Macroscopic cross-sectional views of Hematoxylin&Eosin-
stained hearts isolated from WT and Luma KO mice at 88 weeks. Scale bar: 1 mm (H) Heart 
weight to body weight ratio (HW/BW) and HW to tibia length ratio (HW/TL) of WT versus Luma 
KO mice at 88 weeks (n=9-12 per genotype). p>0.05 according to 2-way ANOVA with Sidak’s 
post-hoc test (A-F, H). 
 
Figure 3: LINC complex protein levels and localizations are unaffected in Luma KO mice. 
A) Western blot analysis of Lamins A/C (A/C), B1 (B1), Sun1, Sun2, Emerin, and Luma in 
wildtype and Luma knockout (KO) hearts. Ponceau stain serves as loading control. Arrowheads 
show the predicted MW of the indicated proteins. MW is denoted in kDa. (n=4/ genotype). (B) 
Immunofluorescence analysis of Luma (green) in wildtype (WT) and Luma KO neonatal 
cardiomyocytes. Cardiomyocytes were stained with alpha actinin (red) and DAPI (blue). Note 
that Luma localizes predominantly to the nuclear envelope, and this signal is absent in Luma 
KO cells. (C, D) Immunofluorescence analysis of (C) neonatal cardiomyocytes and (D) 
fibroblasts isolated from WT and Luma KO hearts. Cells were fixed and stained for nuclear 
lamina proteins Lamin A/C (A/C), Lamin B1 (B1); nuclear envelope protein Emerin (Emd); and 
LINC components Sun1 and Sun2. Cardiomyocytes were stained with alpha actinin (red); 
fibroblasts were stained with phalloidin (red), and DAPI (blue). Note that all proteins remained 
localized to the nuclear envelope in WT and KO cells. Scale bars, 5 μm. B-D, n=30-40 cells/ 
genotype from 3 independent isolations. (E) Scratch wound assay of wildtype and Luma 
knockout neonatal fibroblasts. Note that Luma KO cells were able to migrate at normal rates 
compared to wildtype cells (n=3 biological replicates, n=6-9 scratches/ replicate). p>0.05 
according to the Student’s t-test. 
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Figure 4: Luma KO mice exhibit normal hypertrophic response to pressure overload.  
Echocardiographic measurements of (A) fractional shortening; (B) left ventricular (LV) internal 
diameter, diastole (LVIDd); (C) LV internal diameter, systole, (LVIDs); (D) LV posterior wall, 
diastole (LVPWd); and (E) interventricular septum diameter, diastole (IVSd) at baseline (0) and 
1, 2, and 4 weeks post trans-aortic constriction (TAC) surgery in wildtype (WT) and Luma 
knockout (KO) mice. Note that as expected, cardiac function significantly deceased after TAC 
and chamber dimensions and wall thicknesses increased. However, there were no significant 
changes observed between WT and Luma KO mice. (n=20 males per genotype). (F) Kaplan-
Meier survival analysis showed no significant change in survival between WT and Luma KO 
mice post-TAC. (G) Western blot analysis of Lamins A/C (A/C), B1 (B1), Emerin, Sun2, and 
Luma in wildtype and Luma knockout mice 2 weeks post-TAC and SHAM surgeries. Ponceau 
stain serves as a loading control. (n=4-5/ genotype). Arrowheads show the predicted MW of the 
indicated proteins. MW is denoted in kDa. p>0.05 according to 2-way ANOVA with Sidak’s post-
hoc test (A-E). p=0.87, Mantel-Cox Chi Square test (F). 
 
Figure 5: Contractile function of Luma KO mice is unaffected following beta-adrenergic 
stimulation. Invasive hemodynamics measurements of (A) heart rate; (B) peak pressure; (C) 
maximum rate of pressure change in the left ventricle (dP/dT); (D) minimum rate of (dP/dT); (E) 
exponential tau (index of LV relaxation); and (F) end diastolic pressure (EDP) in wildtype (WT) 
and Luma knockout (KO) mice in response to increasing levels of beta adrenergic agonist 
dobutamine (n=8 males per genotype). p>0.05 according to the Student’s t-test (A-F). 
 
Figure 6: Luma S358L knock-in mice display no overt defects in cardiac function and 
morphology. Echocardiographic measurements of (A) fractional shortening; (B) left ventricular 
(LV) internal diameter, diastole (LVIDd); (C) LV internal diameter, systole, (LVIDs); (D) LV 
posterior wall, diastole (LVPWd); and (E) interventricular septum diameter, diastole (IVSd) over 
the course of 12 months in wildtype (WT) (n=11; 9 females, 2 males), Luma S358L 
heterozygous (HET) mice (n=6; 3 females, 3 males), Luma S358L homozygous (HOM) (n=9; 5 
females, 4 males). (F) Quantitative real-time PCR analysis of fetal genes ANP, BNP, Myh6, 
Myh7, and pro-fibrotic markers Collagen 1a1, and 3a1, in WT and Luma S358L homozygous 
mouse hearts at 2-3months (n=3-6 per genotype). (G) Heart weight to body weight ratio 
(HW/BW) and HW to tibia length ratio (HW/TL) of WT versus Luma KO mice at 47 weeks (n=10 
per genotype). (H) Immunofluorescence analysis adult hearts isolated from wildtype and S358L 
homozygous mice. Sections were stained with antibodies raised against Luma (green), alpha 
actinin (red) and DAPI (blue). Note that Luma S358L has a similar localization to wildtype Luma. 
(I) Western blot analysis of Lamins A/C (A/C), B1 (B1), Emerin, Sun2, and Luma in wildtype and 
Luma S358L knock-in hearts. GAPDH serves as a loading control. Arrowheads show the 
predicted MW of the indicated proteins. MW is indicated in kDa. (n=3/ genotype). p>0.05 
according to 2-way ANOVA with Sidak’s post-hoc test (A-G). 
 
